US 12,486,246 B2
Replication protein A (RPA)-DNA interaction inhibitors
John J. Turchi, Indianapolis, IN (US); and Navnath Gavande, Indianapolis, IN (US)
Assigned to THE TRUSTEES OF INDIANA UNIVERSITY, Bloomington, IN (US)
Appl. No. 17/782,876
Filed by THE TRUSTEES OF INDIANA UNIVERSITY, Bloomington, IN (US)
PCT Filed Dec. 10, 2020, PCT No. PCT/US2020/064191
§ 371(c)(1), (2) Date Jun. 6, 2022,
PCT Pub. No. WO2021/119242, PCT Pub. Date Jun. 17, 2021.
Claims priority of provisional application 62/946,100, filed on Dec. 10, 2019.
Prior Publication US 2023/0056729 A1, Feb. 23, 2023
Int. Cl. C07D 401/04 (2006.01); A61P 35/00 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01)
CPC C07D 401/04 (2013.01) [A61P 35/00 (2018.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01)] 16 Claims
 
1. A compound of the formula

OG Complex Work Unit Chemistry
wherein
R1 is iodo;
R2 is —NH(CH2)3-morpholinyl;
R3 is chloro, fluoro, bromo, or iodo; and
R4 is C1-C6 alkyl;
or a pharmaceutically acceptable salt thereof.